Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada.
Segal Cancer Centre, CIUSSS du Centre-Ouest-de l'Île-de Montréal, Montreal, QC H3T 1E2, Canada.
Curr Oncol. 2023 Nov 30;30(12):10224-10236. doi: 10.3390/curroncol30120744.
The development and use of oral anticancer agents (OAAs) continue to grow, and supporting individuals on OAAs is now a priority as they find themselves taking these drugs at home with little professional guidance. This mapping review provides an overview of the current evidence concerning OAA-supportive adherence interventions, identifying potential gaps, and making recommendations to guide future work. Four large databases and the grey literature were searched for publications from 2010 to 2022. Quantitative, qualitative, mixed-method, theses/dissertations, reports, and abstracts were included, whereas protocols and reviews were excluded. Duplicates were removed, and the remaining publications were screened by title and abstract. Full-text publications were assessed and those meeting the inclusion criteria were retained. Data extracted included the year of publication, theoretical underpinnings, study design, targeted patients, sample size, intervention type, and primary outcome(s). 3175 publications were screened, with 435 fully read. Of these, 314 were excluded with 120 retained. Of the 120 publications, 39.2% ( = 47) were observational studies, 38.3% ( = 46) were quasi-experimental, and 16.7% ( = 20) were experimental. Only 17.5% ( = 21) were theory-based. Despite the known efficacy of multi-modal interventions, 63.7% ( = 76) contained one or two modalities, 33.3% ( = 40) included 3, and 3.3% ( = 4) contained four types of modalities. Medication adherence was measured primarily through self-report ( = 31) or chart review/pharmacy refills ( = 28). Given the importance of patient tailored interventions, future work should test whether having four intervention modalities (behavioral, educational, medical, and technological) guided by theory can optimize OAA-related outcomes.
口服抗癌药物(OAAs)的开发和使用不断增加,由于个体在家中服用这些药物时几乎没有专业指导,因此现在优先支持他们使用 OAAs。本映射综述概述了目前关于 OAA 支持性依从性干预的证据,确定了潜在的差距,并提出了建议,以指导未来的工作。从 2010 年到 2022 年,四个大型数据库和灰色文献都被用来搜索出版物。包括定量、定性、混合方法、论文/学位论文、报告和摘要,而排除了方案和综述。去除重复项后,根据标题和摘要筛选其余出版物。评估全文出版物,并保留符合纳入标准的出版物。提取的数据包括出版年份、理论基础、研究设计、目标患者、样本量、干预类型和主要结局。共筛选了 3175 篇出版物,其中 435 篇全文阅读。其中,314 篇被排除,120 篇被保留。在这 120 篇出版物中,39.2%(=47)为观察性研究,38.3%(=46)为准实验,16.7%(=20)为实验。只有 17.5%(=21)是基于理论的。尽管多模式干预措施已被证明有效,但 63.7%(=76)包含一种或两种模式,33.3%(=40)包含三种模式,3.3%(=4)包含四种模式。药物依从性主要通过自我报告(=31)或图表审查/药房 refill(=28)来测量。鉴于患者量身定制的干预措施的重要性,未来的工作应测试是否有四种干预模式(行为、教育、医疗和技术),并由理论指导,可以优化与 OAA 相关的结果。